ROME THERAPEUTICS Trademark

Trademark Overview

On Thursday, December 23, 2021, a trademark application was filed for ROME THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ROME THERAPEUTICS trademark a serial number of 97187984. The federal status of this trademark filing is EX PARTE APPEAL PENDING as of Monday, September 9, 2024. This trademark is owned by ROME Therapeutics, Inc.. The ROME THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development in the field of cancer and autoimmune disease; pharmaceutical drug development and discovery services in the field of cancer and autoimmune disease; scientific research in the field of pharmaceuticals; providing scientific research information in the field of pharmaceuticals; none of the foregoing relating to gastrointestinal issues
rome therapeutics

General Information

Serial Number97187984
Word MarkROME THERAPEUTICS
Filing DateThursday, December 23, 2021
Status760 - EX PARTE APPEAL PENDING
Status DateMonday, September 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Description of MarkThe mark consists of the stylized word ROME in black with a yellow shadow connected to the left side of the letter O on top of the word THERAPEUTICS in black. The letter R in ROME is incomplete and does not include the left, vertical segment of the letter.
Indication of Colors claimedThe color(s) black and yellow is/are claimed as a feature of the mark.
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesPharmaceutical research and development in the field of cancer and autoimmune disease; pharmaceutical drug development and discovery services in the field of cancer and autoimmune disease; scientific research in the field of pharmaceuticals; providing scientific research information in the field of pharmaceuticals; none of the foregoing relating to gastrointestinal issues

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, December 30, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameROME Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02215

Trademark Events

Event DateEvent Description
Monday, December 27, 2021NEW APPLICATION ENTERED
Thursday, December 30, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 27, 2022ASSIGNED TO EXAMINER
Wednesday, October 12, 2022NON-FINAL ACTION WRITTEN
Wednesday, October 12, 2022NON-FINAL ACTION E-MAILED
Wednesday, October 12, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 12, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 12, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 13, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 5, 2023FINAL REFUSAL WRITTEN
Monday, June 5, 2023FINAL REFUSAL E-MAILED
Monday, June 5, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, August 25, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, August 25, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, August 25, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, December 6, 2023JURISDICTION RESTORED TO EXAMINING ATTORNEY
Monday, August 28, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, August 28, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, December 6, 2023EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, December 5, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, December 6, 2023EX PARTE APPEAL-INSTITUTED
Friday, December 29, 2023SUSPENSION LETTER WRITTEN
Friday, December 29, 2023LETTER OF SUSPENSION E-MAILED
Friday, December 29, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, May 3, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 26, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 26, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, May 3, 2024LETTER OF SUSPENSION E-MAILED
Friday, May 3, 2024SUSPENSION LETTER WRITTEN
Friday, May 3, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, July 15, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 15, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 6, 2024SUBSEQUENT FINAL EMAILED
Friday, September 6, 2024NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Friday, September 6, 2024SUBSEQUENT FINAL REFUSAL WRITTEN
Monday, July 15, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

Related Keywords

therapeutics rome field research scientific pharmaceuticals pharmaceutical disease development cancer autoimmune foregoing